Cancer Treatment Centers of America

Targeted therapy for non-Hodgkin lymphoma


Targeted therapy for non-Hodgkin lymphoma

Targeted therapy drugs are designed to seek out specific gene mutations or proteins on cancer cells and kill those cells, or help other therapies, such as radiation, work better. Monoclonal antibody therapy is a type of targeted therapy that uses immune cells engineered in a laboratory. These cells, when injected back into the body, are designed to target specific cells, killing them or preventing them from growing.

Monoclonal antibodies may be used alone to target lymphoma cells, or in combination with chemotherapy or radiation therapy drugs. For instance, ibritumomab tiuxetan (Zevalin®), a common targeted therapy drug used to treat non-Hodgkin lymphoma, is a combination of a monoclonal antibody and radioactive isotope. Rituximab (Rituxan®), another common targeted therapy for non-Hodgkin lymphoma, may be combined with a chemotherapy agent.

Targeted therapies for non-Hodgkin lymphoma